Patients with acute myeloid leukemia (AML) who fail to achieve complete remission (CR) have a dismal prognosis. Although data suggest that durable remissions can be achieved in approximately 30% of patients with refractory or relapsed AML after allogeneic hematopoietic cell transplantation (HCT), only a small fraction of those patients are offered this therapeutic option. Importantly, patients with primary refractory AML have distinctly better outcomes following allogeneic HCT than those with refractory relapse. Access to suitable donors could be one of the main barriers in these situations. However, with recent developments in the field of allogeneic HCT, such as alternative donor sources, high-resolution HLA-typing, reduced intensity conditioning regimens and improvements in supportive care, this approach has the potential to offer long-term survival for patients with refractory and relapsed AML and should be considered as early after diagnosis as possible. Incorporating novel agents into the conditioning regimen or as post-transplant maintenance therapy could further improve outcomes and render older or medically infirm patients with refractory or relapsed AML eligible for allogeneic HCT. In this review, we summarize existing data on allogeneic HCT in patients with refractory or relapsed AML and explore novel approaches with the potential to improve outcomes in this patient population.
INTRODUCTION
Complete remission (CR), as defined by the International Working Group, 1 can be achieved with infusional cytarabine and an anthracycline in approximately 60-70% of acute myeloid leukemia (AML) patients aged o 60 years. 2 The CR rate, however, drops to about 40-50% in older AML patients (deemed sufficiently functional to undergo induction therapy) with similar induction therapies of standard-dose cytarabine and an anthracycline. [3] [4] [5] According to current practice and National Comprehensive Cancer Network (NCCN) guidelines, allogeneic hematopoietic cell transplantation (HCT) should be offered to patients who achieve CR but are at high risk for relapse, based on various genetic, molecular or clinical risk factors. 6, 7 Patients, who relapse after initial remission, in general, may achieve a second CR in 30-45% of the time when using a more aggressive reinduction regimen [8] [9] [10] [11] [12] [13] [14] ; this rate can be as low as 10-15% in patients whose first CR lasted for o1 year. 15 Patients with primary induction or reinduction failure have poor prognosis with minimal, if any chance of cure using alternative chemotherapy or early-phase clinical trials testing investigational agents. However, several, mostly retrospective studies have shown that long-term survival is possible in selected patients who undergo allogeneic HCT using an HLA-matched sibling donor. 16, 17 Table 1 summarizes recent reports on transplant outcome in AML patients with primary induction failure or in relapse. Because of the time and logistics required to perform an unrelated donor search, there is less experience with HCT from unrelated donors in this scenario; but the limited data available demonstrate that cure is possible in a similar proportion of patients. 18 Furthermore, there are emerging data showing that allogeneic HCT using alternative donor graft sources, such as HLA-haploidentical donors or umbilical cord blood, also could result in long-term disease control and survival in selected patients who have refractory or relapsed AML. These retrospective data emphasize the importance of HLA-typing patients and family members shortly after the diagnosis of AML so that valuable time is not lost in identifying suitable donors should remission induction attempts fail. Herein we review the data and provide recommendations for AML patients who have primary refractory or relapsed disease.
PRIMARY INDUCTION FAILURE
The traditional definition of primary induction failure in patients with AML is the failure to achieve CR after one or two cycles of induction therapy. 19 As above, approximately 30-40% of AML patients younger than 60 years and about 50-60% of older AML patients fail to achieve CR with infusional cytarabine and an anthracycline or similarly aggressive induction therapy. [2] [3] [4] [5] Per current NCCN guidelines for AML, 7 patients initially treated with high-dose cytarabine and who have significant residual disease 7-10 days after completion of induction chemotherapy also should be considered to have experienced induction failure.
In a retrospective analysis of European Group for Blood and Marrow Transplantation (EBMT) data, Nagler et al. 18 reported on 852 AML patients with primary induction failure or refractory relapse who underwent allogeneic HCT. The high-dose conditioning used was cyclophosphamide and either high-dose busulfan or high-dose total body irradiation (TBI) -based regimens. 18 Not surprisingly, in this retrospective data set, the majority of patients (n = 565; 66.7%) received allografts from HLA-identical sibling donors. Although the conditioning regimen (high-dose busulfan vs TBI in combination with cyclophosphamide) did not seem to have a statistically significant impact on outcomes, the large size of the data set allowed for a multivariate analysis to identify risk factors associated with improved outcomes. In this data set, the 2-year overall and disease-free survivals (OS and DFS, respectively) in primary induction failure AML patients who received TBI-based conditioning were 39.7% and 35.2%, respectively, whereas in those who received busulfanbased conditioning, 35.3% and 28.1%, respectively. Posttransplant relapse rates were similar in both groups (48.2% and 49.0%, respectively). Interestingly, in this study, the presence of chronic GVHD did not seem to have an impact on post-transplant relapse rates in a time-dependent analysis.
Craddock et al. 20 analyzed the role of unrelated donor HCT in 168 patients with primary refractory AML, also using EBMT Registry data. The majority of patients (n = 132) received myeloablative conditioning regimens, including 83 patients who underwent TBI-based conditioning. The 5-year OS for the whole cohort in this study was only 22%. It is important to note that patients underwent HCT between 1994 and 2006; supportive care has improved considerably since that time. In multivariate analysis, fewer than three courses of chemotherapy, pretransplant marrow blasts fewer than the median blast percentage (38.5%) and recipient CMV seropositivity were associated with improved OS. Based on this information, a score system was developed, and a good prognostic group (with no adverse prognostic factors) could be identified, who had a 5-year OS of 44 ± 11%. In contrast, patients with all three adverse prognostic factors present had a 0% long-term survival.
Although there is no consensus on the conditioning regimen to be used in this patient population, the majority of retrospective analyses included patients who received high-dose preparative regimens, making this treatment modality available only to younger, medically fit patients with refractory disease. One exception is the reduced-intensity conditioning regimen described by Oran et al., 21 consisting of fludarabine and melphalan. Although the original communication describing this approach does include variable doses of melphalan, it is clear that the use of this regimen followed by administration of an HLA-matched related or unrelated donor graft can result in long-term survival in some older and medically infirm patients who have refractory AML. This study by Oran et al. 21 included a total of 112 patients with high-risk AML and myelodysplastic syndrome (n = 30), including 32 patients with primary refractory and 43 patients with relapsed disease. Estimated 2-year OS was 40% in patients not in CR but who were without circulating blasts, and was 23% for those with active disease and circulating blasts.
In a more recent report from the MD Anderson Cancer Center, Jabbour et al. 22 compared outcomes of 28 primary refractory AML patients who underwent an allogeneic HCT as initial salvage to 149 patients with primary refractory AML who received salvage chemotherapy alone. The 28 patients received grafts from: an HLA-matched sibling, n = 18; an HLA-matched unrelated donor, Abbreviations: BU = busulfan; CLO = clofarabine; DFS = disease-free survival; FLAMSA = fludarabine, cytarabine and amsacrine; HCT = hematopoietic cell transplantation; OS = overall survival; RIC = reduced-intensity conditioning. Studies including patients with other hematological malignancies and disease stages were only included if outcomes were reported separately on patients with refractory or relapsed AML.
Allograft for AML not in remission B Gyurkocza et al n = 7; or an HLA-haploidentical related donor, n = 3. All patients received high-dose cytarabine-based induction, and allotransplant patients received mostly fludarabine-based conditioning regimens (in combination with busulfan, n = 9; melphalan, n = 7 or other). The 3-year OS was 39% for patients undergoing allogeneic HCT, vs only 2%, for patients receiving salvage chemotherapy (P o0.001).
In a repeat, multivariate analysis, including 15 patients with refractory AML who received a subsequent (that is, delayed) allotransplant, allogeneic HCT, as initial salvage therapy, was the most significant predictor of improved DFS and OS. A slightly different approach, using sequential combination chemotherapy immediately followed by an allotransplant with reduced-intensity conditioning, was introduced by Schmid et al.
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This strategy was subsequently adopted by several centers in Germany for the treatment of refractory and relapsed AML. 24, 25 The regimen consisted of fludarabine, cytarabine and amsacrine, followed after 3 days of rest and then by a 4-Gy TBI, cyclophosphamide and ATG-based reduced-intensity conditioning and allotransplant from related or unrelated donors. In the original study by Schmid et al., 23 patients who did not develop GVHD by post-transplant day +120 received a prophylactic donor lymphocyte infusion (DLI). The study included patients with primary induction failure (n = 37) and early (n = 53), refractory (n = 8) or second (n = 5) relapse. The 2-and 4-year OS for the whole cohort was 40% and 32%, respectively. However, patients with primary induction failure had a 2-year OS of 62.5%; OS improved to 87% in the 17 patients who received prophylactic DLI, representing a remarkable clinical outcome in this challenging patient population.
A similar, sequential approach was recently reported by Mohty et al. 26 In this study, 24 patients with primary refractory AML were treated with a sequential regimen consisting of clofarabine and cytarabine, followed by a 3-day rest, and then an allogeneic HCT utilizing a reduced-intensity conditioning regimen combining cyclophosphamide, busulfan (for 2 days) and antithymocyte globulin for 2 days. Patients in CR on posttransplant day +120 received prophylactic DLI. The 1-and 2-year leukemia-free survival was 46% and 29%, respectively.
A recent analysis by Ferguson et al. 27 analyzed the effect of utilizing different definitions of primary induction failure on outcomes, in an attempt to identify patients with genuinely refractory AML earlier during their treatment courses. In this retrospective analysis, the authors included 8907 patients with non-promyelocytic AML, treated with intensive chemotherapy regimens on various clinical trials. Outcomes of patients with refractory disease defined by differing criteria were examined. These criteria included failure to achieve CR after one cycle of induction chemotherapy (RES), less than a 50% reduction in blast numbers with 415% residual blasts after one cycle of induction (REF1) and failure to achieve CR after two courses of induction chemotherapy (REF2). They found that 5-year OS was decreased in patients fulfilling any criteria for refractory disease compared with patients achieving CR after one cycle of chemotherapy: 9% and 8% in patients with REF1 and REF2, respectively, vs 40%. They also found that allogeneic HCT improved OS in both REF1 and REF2 cohorts, and concluded that using the REF1 criteria allowed early identification of patients whose outcome after one course of induction therapy was very poor.
UNTREATED AND REFRACTORY RELAPSE
Owing mostly to logistic reasons such as a lack of immediately available donors or access to a transplant center, few studies have explored the role of allogeneic HCT in patients with untreated relapse. An earlier, but relatively large study was reported by Clift et al. 28 from the Fred Hutchinson Cancer Research Center. This investigation included 126 patients with AML who, between 1974 and 1990, underwent allogeneic HCT using HLA-identical sibling donor grafts during untreated first relapse. The 5-year DFS was 23%. It is important to note, however, that while there was considerable variation in both the conditioning and GVHD prophylaxis regimens (in fact, 4 patients did not receive any GVHD prophylaxis), the majority of patients (n = 71) received a high-dose TBI-based conditioning of 15.75 Gy, which previously was shown to reduce relapse rates, whereas increasing transplant-related deaths. 29, 30 A similar, 29% 4-year DFS was reported by Brown et al., 31 in 40 patients with AML in untreated first relapse undergoing HLA-matched or HLA-mismatched (n = 1) sibling HCT; conditioning included high-dose etoposide, cyclophosphamide and TBI (10 Gy). In this study, the pretransplant marrow blast content did not appear to impact post-transplant relapse risk.
Both of the above studies observed that patients who developed grade ⩾ 2 GVHD had improved DFS and a decreased risk of relapse.
The above data raise the question whether patients with AML in first untreated relapse should undergo allogeneic HCT as initial salvage therapy or should receive reinduction first. Although there are no data to strongly support either option, a theoretical calculation by Appelbaum et al. 32 depicted in Figure 1 suggests that perhaps there would be a benefit for allogeneic HCT in this situation. This is, in part, due to the approximately 15-20% early death rate associated with reinduction attempts. In addition, in patients not achieving second CR after reinduction (that is, in those patients with refractory relapsed AML), cure rates associated with allogeneic HCT are considerably lower than in those with untreated first relapse. Needless to say, this calculation is based on reports of transplants performed in the 1980s and 1990s. The substantial improvements in HLA-typing, donor availability, conditioning regimens and supportive care certainly would merit further studying this question in the context of a clinical trial.
In most retrospective analyses, AML patients in refractory relapse are usually grouped together with those having primary induction failure or with patients in untreated relapse. However, patients with AML in refractory relapse seem to have a distinctly worse prognosis, especially when applying the more stringent definition of having failed the most recent reinduction therapy attempt to define refractory relapse. Earlier publications from the Fred Hutchinson Cancer Research Center in Seattle reported a 10% and 7% 3-5 year DFS after HLA-identical sibling and HLA-matched unrelated donors, respectively, using high-dose cyclophosphamide and TBI-based regimens. 33, 34 In a more recent study, Nagler et al.
18 observed slightly improved outcomes using a multivariate analysis in 852 patients with refractory AML undergoing allogeneic HCT from an HLA-identical sibling or an unrelated donor. They found that the risk of relapse was significantly higher for patients after first or second relapse when compared to those with primary refractory disease. The 2-year DFS in this report was approximately 24% and 15%, respectively, for patients in first and second refractory relapse.
PROGNOSTIC SCORE SYSTEMS
To aid clinical decision making, several attempts were made to identify factors associated with improved outcomes in patients with primary refractory or relapsed AML. A multivariate analysis from the MD Anderson Cancer Center, including 135 patients with refractory AML and myelodysplastic syndrome (n = 24) who underwent allogeneic HCT from related or unrelated donors, showed that Karnofsky performance status, peripheral blast content and tacrolimus exposure (defined by the area under the receiver operating characteristic curve (AUC) of tacrolimus levels during the first 11 days) were predictive of survival. 35 Of note, the authors emphasize that tacrolimus exposure (AUC) over the first 11 days had a log quadratic relationship with the log hazard of death; the death rate initially decreased with AUC, but then increased at higher levels. Based on their data, the authors suggested maintaining optimal tacrolimus exposure during the first 15 days after transplantation, with the optimal target range of serum tacrolimus levels during these days being between 7 and 9 ng/dL.
A larger, more recent report from the Center for International Blood and Marrow Transplant Research (CIBMTR) analyzed 1673 patients with AML with primary induction failure, in first untreated or refractory relapse, and in subsequent relapse undergoing allogeneic HCT following a high-dose busulfan-or TBI-based conditioning regimen. 36 Patients undergoing syngeneic or cord blood transplantations were excluded. Overall survival for the whole cohort of AML patients at 3 years was 19%. Multivariate analysis at 3 years showed worse OS for patients in first relapse after a short (o 6 months) initial CR but better after a longer (46 months) initial CR, when compared to those with primary refractory AML. For patients in first untreated or refractory relapse, the 3-year OS was similar. The presence of circulating blasts, a mismatched unrelated donor, a related donor other than an HLAmatched sibling, a Karnofsky score o90% and poor-risk cytogenetics were identified as additional adverse risk factors. By using these five risk factors, a prognostic score system (the 'Duval Score') was developed, as shown in Table 2 . As depicted in Figure 2 , patients with a score of 0 had a 3-year OS of 42%, while correspondingly, 3-year OS in patients with a score of ⩾ 3 was only 6%.
ALTERNATIVE DONOR SOURCES
Limited HCT data have been published using alternative donor sources, such as HLA-haploidentical donors or umbilical cord blood. A relatively large study from Jaiswal et al. 37 reported encouraging results using HLA-haploidentical grafts after incremental optimization of the conditioning regimen and the use of post-transplant DLI in AML patients not in remission. In this study, 41 patients received myeloablative conditioning, and 21 also received G-CSF-mobilized DLI on days 21, 35 and 60 after HCT. Interestingly, the 18-month incidence of disease progression and DFS were 66% and 25%, respectively, in patients who did not receive DLI, compared with 21% and 62%, respectively, in those who did. Use of a natural killer cell alloreactive donor was associated with a lower incidence of disease progression only in patients who did not receive DLI. The authors concluded that a myeloablative conditioning regimen and early administration of G-CSF-mobilized DLI were factors associated with a decreased incidence of disease progression and improved DFS.
Similarly, only limited data have been published about successful umbilical cord blood transplantation (UCBT) in the setting of refractory AML to date, including anecdotal reports. 38 A larger study by Laughlin et al. 39 compared outcomes after UCBT and unrelated donors in adult patients with acute leukemia. Abbreviations: HCT = hematopoietic cell transplantation; PIF = primary induction failure. Overall score is defined as the sum of the scores for each risk factor. Four risk groups were defined as follows: score of 0, 1, 2, and ⩾ 3. Reproduced, with permission, from Duval et al. Time (years) Survival probability Score = 0 (n = 148), 42% (95% CI, 34% to 50%) Score = 1 (n = 326), 28% (95% CI, 23% to 33%) Score = 2 (n = 342), 15% (95% CI, 11% to 19%) Score = 3 (n = 321), 6% (95% CI, 3% to 9%) 0 Figure 2 . Probability of OS after transplantation for AML in relapse or primary induction failure according to risk score. The 3-year survival rates and 95% confidence intervals (CIs) are indicated. Reproduced, with permission, from Duval et al. 36 A full color version of this figure is available at the Bone Marrow Transplantation journal online.
Although this analysis included a substantial number of patients with advanced disease undergoing UCBT (n = 64), including relapsed leukemia and primary induction failure, and while the overall outcomes were encouraging for the whole cohort, patients with relapsed and refractory AML were lumped together with patients in other disease stages and outcomes were not reported separately. Similarly, Ooi et al. 40 reported on 18 patients with AML who underwent UCBT at a single institution, including six patients in relapse and two patients with primary induction failure. Although the whole cohort had an impressive, 76.6% DFS at 2 years, outcomes of patients with AML not in remission at the time of transplant were not reported separately. Based on individual outcome reports, all four patients in this small cohort who died had relapsed or primary refractory AML at the time of UCBT. Overall, these reports suggest a promising role for UCBT in patients with refractory or relapsed AML, especially in patients who do not have suitable related or unrelated donors readily available. Prospective trials will be needed to further define the role of UCBT in this scenario, to exploit its unique characteristics of reduced time required for accessing the graft and possibly improved disease control.
NOVEL APPROACHES
The above described retrospective analyses included mostly younger patients who were able to tolerate high-dose conditioning regimens. Not only to improve outcomes in this population but also to make this treatment modality available to older and medically infirm patients with refractory or relapsed AML, novel strategies are needed. One such approach is the incorporation of monoclonal antibodies conjugated either to a cytotoxic agent or to a radioactive isotope. This design facilitates a targeted delivery of the antileukemic treatment to the leukemic cells, thereby improving disease control without imposing excessive toxicity to healthy organs. To achieve a favorable biodistribution of a monoclonal antibody conjugated to a cytotoxin or a radioisotope, an ideal antigen would be expressed homogeneously on the tumor cell surface but would lack expression on normal cells. CD33 and CD45 (common leukocyte antigen) are attractive lineage-specific hematopoietic antigens for this purpose and have been successfully developed in the allogeneic HCT setting. 41, 42 Extensive experience already has been published using iodine-131 ( 131 I)-labeled anti-CD45 antibody ( 131 I-BC8; Iomab-B; Actinium Pharmaceuticals, Inc., Edison, NJ, USA) to deliver targeted hematopoietic irradiation to the marrow, spleen and lymph nodes for improved leukemia control without unacceptably high regimen-related toxicity. 43, 44 The CD45 antigen is expressed on the surface of virtually all hematopoietic cells, except mature red cells and platelets. In addition, CD45 expression has been detected in 85-90% of AML. Further, the antigen does not internalize after antibody binding.
In a phase 1 study, elderly patients with advanced AML or myelodysplastic syndrome were treated with escalating doses of 131 I-labeled anti-CD45 antibody, in combination with fludarabine and 2 Gy TBI as conditioning, followed by allogeneic HCT, as shown in Figure 3 . 45 This study enrolled 58 AML patients, 39 of whom had untreated or refractory relapse. The identified maximum tolerated dose of the 131 I-labeled anti-CD45 antibody was 24 Gy administered to the liver and 48 Gy to the marrow. Within the difficult-to-treat subset of elderly patients with AML in untreated or refractory relapse, addition of the 131 I-labeled anti-CD45 antibody to a nonmyeloablative conditioning regimen resulted in a 1-year OS and DFS of 33.%. The leading cause of treatment failure was relapse, the incidence of which was 50% at 1 year post HCT.
On June The use of the 131 I-labeled anti-CD45 antibody in the HLA-haploidentical setting is currently being explored in clinical trials for patients lacking HLA-matched related or unrelated donors (ClinicalTrials.gov Identifier: NCT00589316).
Future directions include conjugating the anti-CD45 antibody with alternative radioisotopes including 90 Y, which is a pure β-emitter lacking the medium-energy gamma component of 131 I, eliminating the need for radiation isolation of patients treated (ClinicalTrials.gov Identifier: NCT01300572). Alpha emitters are currently being tested in preclinical trials.
Another approach that has been extensively explored is the targeting of the CD33 antigen. Like CD45, normal tissue expression of CD33 is largely restricted to hematopoietic cells. Furthermore, this epitope is consistently expressed on the leukemic cells in 490% of AML cases, regardless of patient age or AML mutational profile. Initial trials incorporating 131 I-labeled anti-CD33 antibody (clone p67), however, showed limited success in eradicating leukemic cells, likely owing to the relatively rapid clearance of the 131 I-labeled anti-CD33 antibody, which was thought to result from rapid internalization of the antibodyantigen complex and the release of 131 I from the marrow space. 41 Investigators at the Memorial Sloan Kettering Cancer Center used a slightly different 131 I-labeled murine monoclonal antibody against CD33, designated as M195. 46, 47 Early-phase trials testing a humanized version of this antibody in a 17 patient cohort comprised of patients with primary refractory disease or untreated or refractory relapse. Allogeneic HCT used grafts from HLAidentical or one antigen mismatched related donors. The administration of the 131 I-labeled anti-CD33 antibody was followed by a high-dose conditioning regimen consisting of busulfan and cyclophosphamide. The regimen was well tolerated and resulted in a median survival of 5.7 months; 3 of the 17 patients remained alive at 59+, 87+ and 90+ months posttransplant at the time of publication. 48 However, owing to limitations associated with these radiolabeled antibodies, such as decreased antibody-binding affinity to CD33 after radioiodination and the required radiation isolation, this approach did not advance into more widespread use.
A more recent, promising attempt to target CD33 in the setting of allogeneic HCT is the incorporation SGN-CD33A (vadastuximab talirine; Seattle Genetics, Inc., Bothell, WA, USA) into the conditioning regimen of allogeneic HCT. SGN-CD33A is an antibody-drug conjugate composed of an engineered anti-CD33 monoclonal antibody conjugated to a highly potent DNA crosslinking agent; the latter is released upon internalization of the conjugate. Initial trials showed promising activity in patients with relapsed or refractory AML, who subsequently underwent allogeneic HCT. 49 An ongoing, phase 1-2 study is exploring thẽ Figure 3 . Treatment scheme of conditioning regimen incorporating 131 I-anti-CD45 into a nonmyeloablative regimen as described by Pagel et al. 45 CSP, cyclosporine A; MMF, mycophenolate mofetil.
role of vadastuximab talirine in the setting of allogeneic HCT, both as part of the conditioning regimen as well as in the posttransplant maintenance setting for patients with relapsed or refractory AML.
CONCLUSIONS
In summary, retrospective data show that allogeneic HCT performed in patients with AML with primary refractory disease or in relapse (untreated or refractory) can result in longterm DFS in a subset of patients. There is no consensus on the conditioning regimen, but retrospective studies mostly included younger patients who received high-dose chemotherapy or TBI-based regimens. Also, likely owing to the perceived urgency of these situations and the time required to perform an unrelated donor search, most published reports include patients with HLA-identical sibling donors. This bias may change, as efficiency of HLA-typing and unrelated donor search are improving. Further, the emergence of other alternative donor graft sources such as umbilical cord blood and haploidentical grafts theoretically could be successfully utilized in this scenario. Furthermore, in the appropriate setting, when several donors are available, selecting donors with activating KIR genes could contribute to disease control. 50 Especially intriguing is the recent publication by Jaiswal et al.
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showing success with HLA-haploidentical related donors, who immediately could be accessible when only limited time is available to identify a suitable donor. An additional measure to improve the efficacy of a donor search is early HLA-typing of AML patients and their family members, possibly at the time of diagnosis. Other means to enhance the process include exploring donor options via a preliminary unrelated donor and umbilical cord blood unit searches while patients are receiving induction therapy and information on their risk stratification is emerging. Furthermore, when more than one donor is available, the selection of those persons who express activating KIR genes could contribute to better disease control, so early KIR-typing of suitable donors could also accelerate the donor selection process. The accumulated retrospective data also show that, while allogeneic HCT might provide the best chance for cure in this population, it is still only successful in about 20-40% of patients with primary refractory or relapsed AML. The leading cause of treatment failure is almost uniformly disease progression. Although recent data from Scott et al. 51 (Bone Marrow Transplant Clinical Trials Network 0901, 'MAVERICK' trial) suggest an important role of dose intensity in disease control, past experiences also demonstrated that, while higher doses of TBI do result in reduced relapse risk, this choice came at the price of increased, often fatal gastrointestinal, hepatic and pulmonary toxicities, secondary malignancies and impaired growth and development in children. 29, 30 Additional, novel interventions are needed to improve disease control without excessive additional toxicity. One such approach could be the incorporation of targeted therapy into the conditioning regimen. The use of 131 I-labeled anti-CD45 antibody in combination with a nonmyeloablative conditioning regimen has been associated with considerable success for the treatment of older refractory and relapsed AML patients. Trials incorporating SGN-CD33A (vadastuximab talirine) into the conditioning regimen of allogeneic HCT are currently ongoing.
Another approach could be the use of maintenance therapy early after allogeneic HCT to provide disease control while graft-versus-leukemia (GVL) effects can fully develop. Low-dose azacitidine has been extensively used as maintenance therapy after allogeneic HCT for high-risk AML.
52, 53 The emergence of novel therapies targeting specific mutations (such as FLT3-ITD, IDH1 and IDH2 and so on) could provide viable, personalized options for maintenance therapy after allotransplant. Early posttransplant DLI both in the HLA-matched and HLA-haploidentical setting was also shown to improve disease control that translated into improved DFS and OS.
In conclusion, allogeneic HCT should be considered in AML patients with primary refractory disease or in those with untreated or refractory relapse, preferably in the context of a clinical trial testing such novel approaches. Early HLA-typing of patients and family members and early involvement of the blood and marrow transplant team in the care of newly diagnosed AML patients could facilitate identification of a suitable donor. These maneuvers potentially can overcome some of the barriers to performing allogeneic HCT in patients whose disease does not respond to induction therapy or to salvage therapy. 52 de Lima M, Giralt S, Thall PF, de Padua Silva L, Jones RB, Komanduri K et al.
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010; 116: 5420-5431.
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